Therapeutic opportunities within the DNA damage response

Nature Reviews Cancer

Volumn 15, Issue 3, 2015, Pages 166-180

  Pearl, Laurence H ^a   Schierz, Amanda C ^b,c   Ward, Simon E ^d   Al Lazikani, Bissan ^b   Pearl, Frances M G ^b,d  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Bluefool Innovations   (United Kingdom)

^d UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL NUCLEUS RECEPTOR; CHECKPOINT KINASE 1; CYTOKINE RECEPTOR; DEOXYRIBONUCLEASE I; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE 1; DNA POLYMERASE; DNA TOPOISOMERASE; ENDONUCLEASE; EXONUCLEASE; HELICASE; LIGASE; METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEASE; OLAPARIB; PHOSPHATASE; PHOSPHODIESTERASE; PHOSPHOTRANSFERASE; PROTEIN KINASE; PROTEIN P53; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; SCAFFOLD PROTEIN; SYNTHETASE; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; UBIQUITIN; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASE PAIRING; BIOINFORMATICS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE REGULATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CHROMOSOME SEGREGATION; COLON ADENOCARCINOMA; DEREGULATION; DISEASE ASSOCIATION; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA DAMAGE RESPONSE; DNA END JOINING REPAIR; DRUG TARGETING; EXCISION REPAIR; FAMILIAL CANCER; FANCONI ANEMIA; GENE FUNCTION; GENE MUTATION; GENOMIC INSTABILITY; GERMLINE MUTATION; GLIOBLASTOMA; HOMOLOGOUS RECOMBINATION; HUMAN; INVASIVE CARCINOMA; LOSS OF FUNCTION MUTATION; MISMATCH REPAIR; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SINGLE STRANDED DNA BREAK; SQUAMOUS CELL LUNG CARCINOMA; TELOMERE HOMEOSTASIS; DNA REPAIR; GENETICS; NEOPLASMS;

DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASMS;

EID: 84923397599     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3891     Document Type: Article

References (109)

1. Friedberg, E. C. et al. DNA repair: from molecular mechanism to human disease. DNA Repair 5, 986-996 (2006).
2. Harper, J. W. & Elledge, S. J. The DNA damage response: ten years after. Mol. Cell 28, 739-745 (2007).
3. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
4. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
5. Chang, K. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genet. 45, 1113-1120 (2013).
6. Barber, L. J. et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J. Pathol. 229, 422-429 (2013).
7. Mereniuk, T. R. et al. Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase. Mol. Cancer Ther. 12, 2135-2144 (2013).
8. Brough, R. et al. APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. EMBO J. 31, 1160-1176 (2012).
9. Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637 (2006).
10. Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355 (2008).
11. Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338-345 (2013).
12. Cahill, D. P., Kinzler, K. W., Vogelstein, B. & Lengauer, C. Genetic instability and darwinian selection in tumours. Trends Cell Biol. 9, M57-M60 (1999).
13. Lord, C. J. & Ashworth, A. The DNA damage response and cancer therapy. Nature 481, 287-294 (2012).
14. Bouwman, P. & Jonkers, J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nature Rev. Cancer 12, 587-598 (2012).
15. Curtin, N. J. DNA repair dysregulation from cancer driver to therapeutic target. Nature Rev. Cancer 12, 801-817 (2012).
16. Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nature Rev. Cancer 8, 193-204 (2008).
17. Zhang, J., Stevens, M. F. & Bradshaw, T. D. Temozolomide: mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 5, 102-114 (2012).
18. Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883 (2012).
19. Liu, L. V. et al. Definition of the intermediates and mechanism of the anticancer drug bleomycin using nuclear resonance vibrational spectroscopy and related methods. Proc. Natl Acad. Sci. USA 107, 22419-22424 (2010).
20. Brough, R., Frankum, J. R., Costa-Cabral, S., Lord, C. J. & Ashworth, A. Searching for synthetic lethality in cancer. Curr. Opin. Genet. Dev. 21, 34-41 (2011).
21. Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. Cancer 5, 689-698 (2005).
22. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
23. Lord, C. J., Tutt, A. N. & Ashworth, A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu. Rev. Med. http://dx.doi.org/10.1146/annurev-med-050913-022545 (2014).
24. Janne, P. A., Gray, N. & Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nature Rev. Drug Discov. 8, 709-723 (2009).
25. Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177-183 (2004).
26. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
27. Kanehisa, M. et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 42, D199-D205 (2014).
28. Croft, D. et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 39, D691-D697 (2011).
29. Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808-D815 (2013).
30. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature Genet. 25, 25-29 (2000).
31. Nakazawa, Y. et al. Mutations in UVSSA cause UV-sensitive syndrome and impair RNA polymerase IIo processing in transcription-coupled nucleotide-excision repair. Nature Genet. 44, 586-592 (2012).
32. Buisson, R. et al. Breast cancer proteins PALB2 and BRCA2 stimulate polymerase eta in recombinationassociated DNA synthesis at blocked replication forks. Cell Rep. 6, 553-564 (2014).
33. Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nature Rev. Drug Discov. 5, 993-996 (2006).
34. Patel, M. N., Halling-Brown, M. D., Tym, J. E., Workman, P. & Al-Lazikani, B. Objective assessment of cancer genes for drug discovery. Nature Rev. Drug Discov. 12, 35-50 (2013).
35. Workman, P., Al-Lazikani, B. & Clarke, P. A. Genomebased cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr. Opin. Pharmacol. 13, 486-496 (2013).
36. Antoniou, A. C. et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br. J. Cancer 98, 1457-1466 (2008).
37. Kanchi, K. L. et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nature Commun. 5, 3156 (2014).
38. Bancroft, E. K. et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur. Urol. 66, 489-499 (2014).
39. Tischkowitz, M. et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate 68, 675-678 (2008).
40. Rustgi, A. K. Familial pancreatic cancer: genetic advances. Genes Dev. 28, 1-7 (2014).
41. Howlett, N. G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606-609 (2002).
42. McKusick, V. A. A. Catalog of Human Genes and Genetic Disorders (John Hopkins Univ. Press, 1998).
43. Richardson, C. J. et al. MoKCa database-mutations of kinases in cancer. Nucleic Acids Res. 37, D824-D831 (2009).
44. Espinosa, O., Mitsopoulos, K., Hakas, J., Pearl, F. & Zvelebil, M. Deriving a mutation index of carcinogenicity using protein structure and protein interfaces. PLoS ONE 9, e84598 (2014).
45. Khoo, K. H., Verma, C. S. & Lane, D. P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nature Rev. Drug Discov. 13, 217-236 (2014).
46. Weinstein, J. N. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genet. 45, 1113-1120 (2013).
47. Collins, F. S. & Barker, A. D. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci. Am. 296, 50-57 (2007).
48. Kuhn, E. et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genomewide analyses. J. Natl Cancer Inst. 104, 1503-1513 (2012).
49. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
50. Pfeifer, G. P. et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21, 7435-7451 (2002).
51. Alexandrov, L. B. & Stratton, M. R. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr. Opin. Genet. Dev. 24, 52-60 (2014).
52. TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
53. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
54. Lindstrom, M. S. NPM1/B23: a multifunctional chaperone in ribosome biogenesis and chromatin remodeling. Biochem. Res. Int. 2011, 195209 (2011).
55. Nikolaev, S. I. et al. A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. Cancer Res. 72, 6279-6289 (2012).
56. Hoe, K. K., Verma, C. S. & Lane, D. P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nature Rev. Drug Discov. 13, 217-236 (2014).
57. Riffell, J. L., Lord, C. J. & Ashworth, A. Tankyrasetargeted therapeutics: expanding opportunities in the PARP family. Nature Rev. Drug Discov. 11, 923-936 (2012).
58. Martin, S. A. et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 17, 235-248 (2010).
59. van Pel, D. M., Stirling, P. C., Minaker, S. W., Sipahimalani, P. & Hieter, P. Saccharomyces cerevisiae genetics predicts candidate therapeutic genetic interactions at the mammalian replication fork. G3 (Bethesda) 3, 273-282 (2013).
60. Chatr-Aryamontri, A. et al. The BioGRID interaction database: 2013 update. Nucleic Acids Res. 41, D816-D823 (2013).
61. Paul, J. M., Templeton, S. D., Baharani, A., Freywald, A. & Vizeacoumar, F. J. Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell. Trends Mol. Med. 20, 704-715 (2014).
62. Franchitto, A. et al. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase. Oncogene 22, 2110-2120 (2003).
63. Bulusu, K. C., Tym, J. E., Coker, E. A. & Schierz, A. C. & Al-Lazikani, B. CanSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Res. 42, D1040-D1047 (2014).
64. Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107 (2012).
65. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249 (2000).
66. Fauman, E. B., Rai, B. K. & Huang, E. S. Structurebased druggability assessment-identifying suitable targets for small molecule therapeutics. Curr. Opin. Chem. Biol. 15, 463-468 (2011).
67. Mehra, R., Serebriiskii, I. G., Burtness, B., Astsaturov, I. & Golemis, E. A. Aurora kinases in head and neck cancer. Lancet Oncol. 14, e425-e435 (2013).
68. Weiss, L. & Efferth, T. Polo-like kinase 1 as target for cancer therapy. Exp. Hematol. Oncol. 1, 38 (2012).
69. Hornbeck, P. V. et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined posttranslational modifications in man and mouse. Nucleic Acids Res. 40, D261-D270 (2012).
70. Landre, V., Rotblat, B., Melino, S., Bernassola, F. & Melino, G. Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities. Oncotarget 5, 7988-8013 (2014).
71. Jacq, X., Kemp, M., Martin, N. M. & Jackson, S. P. Deubiquitylating enzymes and DNA damage response pathways. Cell Biochem. Biophys. 67, 25-43 (2013).
72. Lim, K. H. & Baek, K. H. Deubiquitinating enzymes as therapeutic targets in cancer. Curr. Pharm. Des. 19, 4039-4052 (2013).
73. Liang, Q. et al. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nature Chem. Biol. 10, 298-304 (2014).
74. Fan, Y. H. et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 4, e867 (2013).
75. Nishi, R. et al. Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity. Nature Cell Biol. 16, 1016-1026 (2014).
76. Tomkinson, A. E., Howes, T. R. & Wiest, N. E. DNA ligases as therapeutic targets. Transl. Cancer Res. 2, 1219 (2013).
77. van Pel, D. M. et al. An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development. PLoS Genet. 9, e1003254 (2013).
78. Panda, H. et al. Amino acid Asp181 of 5'-flap endonuclease 1 is a useful target for chemotherapeutic development. Biochemistry 48, 9952-9958 (2009).
79. Dorjsuren, D. et al. Complementary non-radioactive assays for investigation of human flap endonuclease 1 activity. Nucleic Acids Res. 39, e11 (2011).
80. McWhirter, C. et al. Development of a high-throughput fluorescence polarization DNA cleavage assay for the identification of FEN1 inhibitors. J. Biomol. Screen 18, 567-575 (2013).
81. Nguyen, G. H. et al. A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. Chem. Biol. 20, 55-62 (2013).
82. Aggarwal, M., Banerjee, T., Sommers, J. A. & Brosh, R. M. Jr. Targeting an Achilles' heel of cancer with a WRN helicase inhibitor. Cell Cycle 12, 3329-3335 (2013).
83. D'Antonio, M. et al. Recessive cancer genes engage in negative genetic interactions with their functional paralogs. Cell Rep. 5, 1519-1526 (2013).
84. Turner, N. C. et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27, 1368-1377 (2008).
85. Allinson, S. L. DNA end-processing enzyme polynucleotide kinase as a potential target in the treatment of cancer. Future Oncol. 6, 1031-1042 (2010).
86. Oliver, A. W., Swift, S., Lord, C. J., Ashworth, A. & Pearl, L. H. Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep. 10, 990-996 (2009).
87. Bastian, M., Heymann, S. & Jacomy, M. Gephi: an open source software for exploring and manipulating networks International AAAI Conference on Weblogs and Social Media (2009).
88. TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
89. TCGA. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
90. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
91. TCGA. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
92. TCGA. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49 (2013).
93. TCGA. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
94. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L. & Ideker, T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27, 431-432 (2011).
95. Kupfer, G. M. Fanconi anemia: a signal transduction and DNA repair pathway. Yale J. Biol. Med. 86, 491-497 (2013).
96. Daley, J. M., Kwon, Y., Niu, H. & Sung, P. Investigations of homologous recombination pathways and their regulation. Yale J. Biol. Med. 86, 453-461 (2013).
97. Murray, J. M. & Carr, A. M. Smc5/6: a link between DNA repair and unidirectional replication? Nature Rev. Mol. Cell Biol. 9, 177-182 (2008).
98. Pastwa, E. & Blasiak, J. Non-homologous DNA end joining. Acta Biochim. Pol. 50, 891-908 (2003).
99. Wang, Z., Wu, X. & Friedberg, E. C. Molecular mechanism of base excision repair of uracil-containing DNA in yeast cell-free extracts. J. Biol. Chem. 272, 24064-24071 (1997).
100. Eker, A. P., Quayle, C., Chaves, I. & van der Horst, G. T. DNA repair in mammalian cells: Direct DNA damage reversal: elegant solutions for nasty problems. Cell. Mol. Life Sci. 66, 968-980 (2009).
101. Larrea, A. A., Lujan, S. A. & Kunkel, T. A. SnapShot: DNA mismatch repair. Cell 141, 730.e1 (2010).
102. Jaspers, N. G. & Hoeijmakers, J. H. DNA repair. Nucleotide excision-repair in the test tube. Curr. Biol. 5, 700-702 (1995).
103. Prakash, S., Johnson, R. E. & Prakash, L. Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function. Annu. Rev. Biochem. 74, 317-353 (2005).
104. Chambers, A. L. & Downs, J. A. The RSC and INO80 chromatin-remodeling complexes in DNA doublestrand break repair. Prog. Mol. Biol. Transl. Sci. 110, 229-261 (2012).
105. Verdun, R. E. & Karlseder, J. Replication and protection of telomeres. Nature 447, 924-931 (2007).
106. Bardin, A. J. & Amon, A. Men and sin: what's the difference? Nature Rev. Mol. Cell Biol. 2, 815-826 (2001).
107. Jackson, S. P. & Durocher, D. Regulation of DNA damage responses by ubiquitin and SUMO. Mol. Cell 49, 795-807 (2013).
108. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
109. Marston, A. L. Chromosome segregation in budding yeast: sister chromatid cohesion and related mechanisms. Genetics 196, 31-63 (2014).